Grant will help establish proof of concept for vaccines that protect against existing and new strains.
MigVax Gets Millions To Develop Variant-Proof Vaccine
The coalition, headquartered in Norway, also is funding a similar project at the University of Saskatchewan in Canada.
Both projects aim to establish preclinical proof of concept for “variant-proof” vaccines that protect against existing and new SARS-CoV-2 variants. The vaccine platforms may also be applicable for developing vaccines that are protective against a broad range of beta coronaviruses, as well as unknown pathogens with pandemic potential that have yet to emerge.
“In countries with sufficient access to them, vaccines are now breaking the link between Covid-19 infection and severe illness or death, and enabling life to return to something approaching normality,” said the coalition’s CEO, Dr. Richard Hatchett.
As long as the threat of new emerging variants “continues to hang over us all,” Hatchett said, developing globally accessible vaccines that are broadly protective is imperative for global health security.
Established in 2020, MigVax is an affiliate startup of MIGAL Galilee Research Institute, a research and development center of the Ministry of Science and Technology. Early in the pandemic, MigVax set out to modify for humans a well-established coronavirus vaccine for the immunization of poultry.
MigVax CEO David Zigdon said the oral vaccine tablet could help the world return to a “new normal.” This is a “sub-unit” vaccine, containing pieces of coronavirus protein (not live or dead virus) delivered orally to the immune system via a bacterial protein to stimulate antibodies and immune cells against coronavirus in mucosa, blood and cells.
“Oral boosters such as our MigVax-101, which could protect against emerging COVID-19 variants, will help health organizations transition from panic mode to routine, reducing the cost and expanding the reach of their vaccination programs.
“We will take full advantage of this grant to bring it to market faster and explore the potential use of our vaccine platform against other coronaviruses,” said Zigdon.
MigVax released results on June 10 from preclinical tests on lab rats that demonstrated the potential effectiveness of MigVax-101 as an antibody booster for previously vaccinated people.
MigVax says its vaccine candidate is uniquely positioned to tackle new variants because the subunit can be adapted quickly to novel variants.
And its protein components are stable, meaning the vaccine may remain effective for longer periods before requiring a booster.
Furthermore, MigVax-101 could be more acceptable to a wider population, including people wary of receiving injections of genetic or viral material, as well as infants, children, pregnant women and others.
“The results of this trial increase our confidence that our MigVax-101 subunit oral vaccine will make a positive contribution to a world coming to grips with the new post-pandemic reality,” said professor Itamar Shalit, MigVax’s infectious disease expert.
Produced in association with Israel21C.